Workflow
减肥用减肥药靠谱吗 医学专家谈科学减重:不存在既安全又轻松的减肥捷径
Zhong Guo Qing Nian Bao·2025-07-15 01:16

Core Insights - The obesity rate among adults in China continues to rise, with approximately 30% of individuals with a normal BMI having issues such as excessive body fat and insufficient muscle mass [1][5] - Novo Nordisk's semaglutide injection, known as Ozempic, has been approved for long-term weight management in China, allowing eligible patients to access the medication through hospitals under medical supervision [1][2] Group 1: Medical Insights - The use of semaglutide mimics the action of the natural hormone GLP-1, suppressing appetite and increasing feelings of fullness to aid weight loss [2] - Medical professionals emphasize that lifestyle changes should be prioritized over medication, as drug interventions primarily address short-term issues [3] - There are concerns regarding the long-term efficacy of weight loss medications, as the body may adapt to the drug, leading to diminished effects over time [3] Group 2: Patient Behavior and Risks - Some patients resort to extreme dieting methods, such as very low-calorie diets or purging, which can lead to severe health complications [4] - Psychological factors play a significant role in obesity, with many individuals using food as a coping mechanism for stress and anxiety [3][4] - The definition of obesity is evolving from solely relying on BMI to considering metabolic health, indicating that individuals with normal BMI can still be classified as obese if they have metabolic dysfunction [5] Group 3: Public Health and Education - There is a need for increased public awareness regarding safe and effective weight management practices, as misleading marketing can promote unrealistic expectations [5] - The "Healthy China 2030" initiative encourages integrating health promotion into public policy and fostering a supportive environment for healthy lifestyles [6] - Companies are encouraged to incorporate weight management into their corporate culture, promoting health initiatives among employees [6]